Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2

BJU International

Volumn 108, Issue 4, 2011, Pages 531-537

  Aziz, Anis ^a   Lessard, Annie ^b   Moore, Katherine ^b   Hovington, Hélène ^b   Latulippe, Eva ^c   Larue, Hélène ^b   Fradet, Yves ^b   Lacombe, Louis ^b  

^a Urology Service   (Canada)

^b Laboratoire d'Uro Oncologie Expérimentale   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

bladder cancer; carcinoma invading bladder muscle; COX 2 expression; disease outcome

Indexed keywords

CYCLOOXYGENASE 2; ENZYME ANTIBODY; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; AGED; ANALYTICAL PARAMETERS; BLADDER CANCER; BLADDER MUSCLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79961093491     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09909.x     Document Type: Review

References (31)

1. Société canadienne du Cancer/Institut National du Cancer du Canada. Statistiques canadiennes Sur Le cancer. Stat Can 2008 1: 1-112
2. Stein JP, Lieskovsky G, Cote R, et al,. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75 (Pubitemid 32120143)
3. Shirahama T, Arima J, Akiba S, Sakakura C,. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 188-93 (Pubitemid 32623056)
4. Moyad MA,. An introduction to aspirin, nsaids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in Bladder carcinogenesis: part II. Semin Urol Oncol 2001; 19: 306-16 (Pubitemid 33140916)
5. Mohammed SI, Bennett PF, Craig BA, et al,. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002; 62: 356-8 (Pubitemid 34106402)
6. Turini ME, Dubois RN,. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002; 53: 35-57 (Pubitemid 34177870)
7. Fosslien E,. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001; 31: 325-48 (Pubitemid 32988657)
8. Fosslien E,. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30: 3-21 (Pubitemid 30078300)
9. Janne PA, Mayer RJ,. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342: 1960-8. (Pubitemid 30419092)
10. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK,. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82: 1364-9. (Pubitemid 30145360)
11. Qin J, Yuan J, Li L, et al,. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cdna, and their combination on the growth of human bladder cancer cells. Biomed Pharmacother 2009; 63: 241-8
12. Mohammed SI, Craig BA, Mutsaers AJ, et al,. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003; 2: 183-8
13. Wulfing C, Eltze E, Von SD, Wulfing P, Hertle L, Piechota H,. Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol 2004; 45: 46-52 (Pubitemid 37548993)
14. Kim SI, Kwon SM, Kim YS, Hong SJ,. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002; 60: 816-21 (Pubitemid 35300345)
15. Shariat SF, Matsumoto K, Kim J, et al,. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 2003; 170: 985-9 (Pubitemid 36999617)
16. Lin D, Wei LJ, Ying Z,. Checking the cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80: 557-72. Ref Type: Journal (Full)
17. Mohammed SI, Knapp DW, Bostwick DG, et al,. Expression of cyclooxygenase-2 (COX-2) in human invasive Transitional Cell Carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647-50
18. Marnett LJ,. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89
19. Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J, Wada S,. Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 2001; 165: 1468-72 (Pubitemid 32410216)
20. Margulis V, Shariat SF, Ashfaq R, et al,. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol 2007; 177: 1163-8 (Pubitemid 46216369)
21. Khor LY, Bae K, Pollack A, et al,. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007; 8: 912-20 (Pubitemid 47495777)
22. Fabi A, Metro G, Papaldo P, et al,. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 2008; 62: 717-25
23. Oku S, Higashi M, Imazono Y, et al,. Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract. BJU Int 2003; 91: 109-14
24. Mohammed SI, Dhawan D, Abraham S, et al,. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 2006; 5: 329-36
25. Hattori K, Iida K, Joraku A, Tsukamoto S, Akaza H, Oyasu R,. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 2006; 97: 640-3
26. Dragovich T, Burris H, III, Loehrer P, et al,. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 2008; 31: 157-62 (Pubitemid 351519167)
27. Cascinu S, Scartozzi M, Carbonari G, et al,. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol 2007; 30: 526-30 (Pubitemid 47537955)
28. Agarwala A, Fisher W, Bruetman D, et al,. Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the hoosier oncology group. J Thorac Oncol 2008; 3: 374-9 (Pubitemid 351489477)
29. Mutter R, Lu B, Carbone DP, et al,. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009; 15: 2158-65
30. Gaffney DK, Winter K, Dicker AP, et al,. A phase II study of acute toxicity for celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys 2007; 67: 104-9 (Pubitemid 44959486)
31. Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW,. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 2008; 7: 897-904 (Pubitemid 351551043)